Kiniksa (KNSA) plans to discontinue the development of abiprubart in Sjogren’s Disease. The company will explore strategic alternatives for the asset. Kiniksa has exercised its right to terminate its exclusive license agreement for mavrilimumab with MedImmune.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue